Extension of mepolizumab injection intervals as potential of saving costs in well controlled patients with severe eosinophilic asthma()()

BACKGROUND: Present guidelines recommend a life-long therapy with mepolizumab in patients suffering from severe eosinophilic asthma as several studies proved the disadvantages of treatment cessation. This study evaluated the possibility of extending the dosage intervals of mepolizumab in those patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Bölke, Georg, Tong, Xunliang, Zuberbier, Torsten, Bousquet, Jean, Bergmann, Karl-Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization 2022
Materias:
Full-Length Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527939/
https://www.ncbi.nlm.nih.gov/pubmed/36254185
http://dx.doi.org/10.1016/j.waojou.2022.100703

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527939/
https://www.ncbi.nlm.nih.gov/pubmed/36254185
http://dx.doi.org/10.1016/j.waojou.2022.100703

Ejemplares similares